Clinical trials: Cat Hypersensitivity
Perennial Allergic Rhinitis
Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic Rhinitis
The goal of this clinical trial is to learn if a probiotic formulation consisting of multiple bacterial strains has a positive effect on the quality of life of participants with chronic perennial allergic rhinitis symptoms.
- Trial name
- AllerGo (NCT07157462)
- Testing
- Multi-species probiotic powder for oral solution. Dietary supplement containing six bacterial strains (Lactobacillus and Bifidobacterium species)
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Winclove B.V.
Cat Allergy
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel, synthetic, allergen derived peptide desensitising vaccine currently being developed for…
- Trial name
- NCT01383603
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Circassia Limited
Rhinoconjunctivitis
Phase III Cat-PAD Study
The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.
- Trial name
- NCT01620762
- Testing
- Cat-PAD
- Where
- 118 sites in United States, Belgium and 7 more
- Volunteers
- 1,408 people
- Sponsor
- Circassia Limited
Allergy, Allergic Asthma
Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation
This is a multicenter, prospective, observational study to evaluate the analytical performance of the Abionic IgE Multi-Allergen Test Panel on the abioSCOPE® device in a U.S.
- Conditions
- Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust
- Trial name
- NCT04401631
- Testing
- Blood Collection
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abionic SA
Cat Allergy
Phase III Cat-PAD Follow-on Study
The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment.
- Trial name
- NCT02040844
- Testing
- Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
- Volunteers
- 430 people
- Sponsor
- Circassia Limited
Allergic Conjunctivitis
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy.
- Trial name
- NCT06602726
- Testing
- REGN1908, REGN1909
- Where
- 4 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Regeneron Pharmaceuticals
Cat Allergy
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel synthetic, allergen derived peptide desensitizing vaccine currently being developed for the…
- Trial name
- NCT01383590
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Circassia Limited
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Conjunctivitis Allergic
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
The purpose of this Patient Identification and Characterization (PIC) study is to collect information and perform limited allergy-related procedures to determine if participants can qualify for cat and/or birch tree pollen…
- Trial name
- NCT07710846
- Testing
- Noninterventional
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma, Bronchial, Rhinitis, Allergic, Perennial
Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)
The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.
- Trial name
- NCT00092105
- Testing
- MK0476, montelukast sodium
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Rhinoconjunctivitis
Paediatric Safety Study in Cat-PAD
Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects
- Trial name
- NCT01921257
- Testing
- Cat-PAD
- Where
- 3 sites in Poland
- Volunteers
- 16 people
- Sponsor
- Circassia Limited
Allergic Asthma, Allergy
Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With Asthma
This is a randomized, double blind, cross-over study designed to determine the concentration of airborne cat allergen inducing bronchial response in asthmatic subjects allergic to cat, during allergen exposures in the Alyatec…
- Conditions
- Allergic Asthma, Allergy, Allergy to Cats
- Trial name
- NCT04678063
- Testing
- Exposure to dose A and dose B of cat allergen, Exposure to a single dose of cat allergen
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Alyatec
Cat Allergy
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00867906
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Circassia Limited
Asthma, Allergy
Efficacy of Air Cleaners in Asthmatics Allergic to Cat in ALYATEC Environmental Exposure Chamber
The aim of this study is to determine the efficacy of Rowenta® "Intense Pure Air XL" air cleaner on the early and late bronchial response, in cat-allergic asthmatic patients during an allergen exposure in ALYATEC environmental…
- Trial name
- NCT03928561
- Testing
- Active intense Pure Air XL air cleaner
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Alyatec
Cat Allergy, Rhinoconjunctivitis
An Optional Two Year Follow Up Study to Study CP005A
Cat allergy is an increasingly prevalent condition affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01604018
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Circassia Limited
Cat Allergy
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00729508
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Circassia Limited
Cat Induced Allergic Rhinitis
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms
This is a single-center, prospective, randomized, double-blind, placebo-controlled, two-way crossover study. A live cat challenge model will be used for exposing subjects to Fel d1.
- Trial name
- NCT00637884
- Testing
- Fexofenadine HCl
- Volunteers
- 70 people
- Sponsor
- Sanofi
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Rhinoconjunctivitis
Phase II HDM-SPIRE Safety and Efficacy Study
The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, Quality of Life and Sleep…
- Trial name
- NCT02150343
- Testing
- HDM-SPIRE
- Where
- 98 sites in United States, Canada and 6 more
- Volunteers
- 715 people
- Sponsor
- Circassia Limited
Allergy and Immunology
Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects
This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and female subjects.
- Trial name
- NCT02559258
- Where
- Australia
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tunitas Therapeutics, Inc.